#### **PCT**

## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: WO 95/07994 (11) International Publication Number: C12N 15/86, A61K 35/76, 39/12 **A3** (43) International Publication Date: 23 March 1995 (23.03.95) (21) International Application Number: PCT/US94/10469 (81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SL, SK, TJ, TT, UA, UZ, (22) International Filing Date: 15 September 1994 (15.09.94) VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, (30) Priority Data: CF, CG, CL, CM, GA, GN, ML, MR, NE, SN, TD, TG). 08/122,791 15 September 1993 (15.09.93) ARIPO patent (KE, MW, SD). US 08/198,450 18 February 1994 (18.02.94) HS Published With international search report. (71) Applicant: VIAGENE, INC. [US/US]; 11055 Roselle Street, Before the expiration of the time limit for amending the San Diego, CA 92121 (US). claims and to be republished in the event of the receipt of (72) Inventors: DUBENSKY, Thomas, W., Jr.; 12729 Via Felino, Del Mar, CA 92014 (US). IBANEZ, Carlos, E.; 13592 amendments. Millpond Way, San Diego, CA 92129 (US). CHANG, (88) Date of publication of the international search report: Stephen, M., W.; 9838 Via Cacares, San Diego, CA 92129 17 August 1995 (17.08.95) (US). JOLLY, Douglas, J.; 277 Hillcrest Drive, Leucadia, CA 92024 (US). DRIVER, David, A.; 5142 Biltmore Street, San Diego, CA 92117 (US). POLO, John, M.; 1222 Reed Avenue, No. 4, San Diego, CA 92109 (US). (74) Agents: McMASTERS, David, D. et al.; Seed and Berry, 6300 Columbia Center, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).

#### (54) Title: RECOMBINANT ALPHAVIRUS VECTORS

#### (57) Abstract

The present invention provides composition and methods for utilizing recombinant alphavirus vectors.

#### FOR THE PURPOSES OF INFORMATION ONLY

ε,

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

ΑT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IB.	Ireland	NZ	New Zealand
B.J	Benin	CT	Îtaly	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic	SD	Sudan
CG	Congo		of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SI	Slovenia
CI	Côte d'Ivoire	KZ	Kazakhstan	SK	Slovakia
CM	Cameroon	LI	Liechtenstein	SN	Senegal
CN	China	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LO	Luxembourg	TG	Togo
CZ	Czech Republic	LV	Latvia	TĴ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA.	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Viet Nam
GA	Gehon	4,44		***	A 100 TARTE

Inter onal Application No.
PCT/US 94/10469

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N15/86 A61K35/76 A61K39/12 According to international Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12N A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X J. VIROLOGY, vol.63, no.12, December 1989, USA 8-10, pages 5216 - 5227 21-26,29 GRAKOUI A. ET AL. 'A cis-acting mutation in the Sindbis Virus junction region which affect subgenomic RNA synthesis' See the document in its entirety Y See the documnet in its entirety 2,3,5-7, 11-21, 27-30 Further documents are listed in the continuation of box C. Patent family members are listed in annex. ĮX ∣ Special categories of cited documents: "I" later document published after the international filing date or priority date and not in conflict with the application but eated to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention earlier document but published on or after the international filing date document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to 1. document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled "O" document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 17.07.95 24 March 1995 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentiaan 2 NI. - 2280 HV Ripswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Germinario C.

Form PCT/ISA-210 (second sheet) (July 1992)

2

Intc onal Application No PCT/US 94/10469

C 1C	DOMESTIC AND THE STATE OF THE S	PCT/US 94/10469
Calegory *	GUIDON OF CONSIDERED TO BE RELEVANT	
ongin y	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J. VIROLOGY, vol.65, no.5, May 1991, USA pages 2501 - 2510 RAJU R. ET AL. 'Analysis of Sindbis Virus promoter recognition in vivo using novel vectors with two subgenomic mRNA promoters'	2-6, 8-10, 21-24, 26,30
1	See the document in its entirety See document in its entirety	1,7,8, 11-20, 25,27-29
Ý	J. VIROLOGY, vol.66, no.2, February 1992, USA pages 857 - 864 HERZT. J. M. ET AL 'Utilisation of heterologous alphavirus junction sequences as promoter by Sindbis virus' See Results and Material and Methods	1-30
r	WO,A,92 10578 (BIOPTION) 25 June 1992 See page 3-13, examples 2-4, claims 12 to 41	1-30
Y	SCIENCE, vol.243, 3 March 1989, WASHINGTON pages 1188 - 1191 CHENG XIONG ET AL. 'Sindbis virus: an efficient broad host range vector fo rgene expression in animal cells' See the document in its entirety	1-30
	US,A,5 091 309 (WASHINGTON UNIVERSITY) 25 February 1992 cited in the application See Summary and example 2	1-30

Form PCT ISA 210 (continuation of second sheet) (July 1992)

International application No.

PCT/US 94/10469

# Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet) Box i This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons: Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a). Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet) This International Searching Authority found multiple inventions in this international application, as follows: please see enclosure../..! As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searches without effort justifying an additional fee, this Authority did not invite payment of any additional fee. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: 4. X No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-6,29,30 and dependent claims (i.e. 1-30) The additional search fees were accompanied by the applicant's protest. Remark on Protest No protest accompanied the payment of additional search fees.

#### LACK OF UNITY OF INVENTION

1. Claims: 1-6,29,30 and claims dependent (i.e.: 1-30)

2. Claims: 31,34 and claims dependent

3. Claims: 37,38,40,44,56,57,63,72,75-79,84 and

claims dependent

4. Claims: 85,86 and claims dependent

The present application comprises 28 independent claims which identify four independent inventions.

The subject matter of the first invention is represented by the alpha-virus vector of claims 1 to 6, 29, 30 and claims dependent thereon. The vector is characterized by the feature of comprising a modified or inactivated viral junction region, which implies the prevention of the transcription of the subgenomic fragment and therefore the defective or blocked expression of the alpha virus structural proteins.

The subject matter of the second invention is the expression cassette of claims 31 and 34 and claims dependent thereon. The cassette comprises a promoter which directs the expression of alpha virus structural proteins. This second invention is not directed to an alpha virus vector and does not comprise the characterizing feature of the previous invention, namely a modified junction region. Should in any case this region be present in the cassette, it would be fully functional (contrary to the first invention) to allow the expression of the viral structural protein.

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

The subject matter of the third invention is represented by the alpha virus particles and cells infected by said particles of claims 37, 38, 40, 44, 56, 57, 63, 72, 75-79, 84 and claims dependent thereon.

The lack of unity of this invention versus the alpha vector of the first invention derives from the fact the alpha vector is not necessarily packaged into a viral particle of the third invention.

Moreover the viral particles do not comprise an inactivated or modified junction region, which is the characterizing feature of the first invention.

The fourth invention is the layered vector initiation system of claims 85; 86 and claims dependent thereon, which is in no way limited to alpha virus.

information on patent family members

Inte. Jonal Application No PCT/US 94/10469

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9210578	25-06-92	AU-B- AU-A- EP-A- JP-T-	656545 9078791 0561890 6504198	09-02-95 08-07-92 29-09-93 19-05-94
US-A-5091309	25-02-92	NONE		